DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
The generic ingredient in SOLIQUA 100/33 is insulin glargine; lixisenatide. There are forty drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the insulin glargine; lixisenatide profile page.
Generic Entry Opportunity Date for 208673
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Suppliers and Packaging for NDA: 208673
Profile for product number 001
|Active Rx/OTC/Discontinued:||RX||Dosage:||SOLUTION;SUBCUTANEOUS||Strength||300 UNITS/3ML;99MCG/3ML (100 UNITS/ML;33MCG/ML)|
|Approval Date:||Nov 21, 2016||TE:||RLD:||Yes|
|Regulatory Exclusivity Expiration:||Jul 27, 2021|
|Regulatory Exclusivity Use:||NEW CHEMICAL ENTITY|
|Regulatory Exclusivity Expiration:||Nov 21, 2019|
|Regulatory Exclusivity Use:||NEW COMBINATION|
|Patent:||Start Trial||Patent Expiration:||Nov 11, 2030||Product Flag?||Y||Substance Flag?||Delist Request?|
Complete Access Available with Subscription